Tag Archives | ACC

Cholesterol Stocks Clobbered: Good Clinical Results But High Expectations

Upbeat Drug Study Data from an Amgen Cholesterol Trial but Stocks are Clobbered Because of Higher Expectations LDL cholesterol is a Toxic Risk Factor Results from a long-term study on the efficacy of a new generation of LDL cholesterol reducing drugs fell short of expectations and clobbered four stocks: Amgen (AMGN) , Esperion (ESPR), The […]

Continue Reading 0